BMRA - Biomerica, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
2.9956
+0.0656 (+2.24%)
As of 2:49PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.9300
Open2.9500
Bid2.9400 x 3100
Ask3.0500 x 800
Day's Range2.9400 - 2.9956
52 Week Range1.6000 - 3.6900
Volume5,317
Avg. Volume20,915
Market Cap29.413M
Beta (3Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Biomerica Reports 1st Quarter Fiscal 2020 Financials

    Biomerica, Inc. (BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 for the same period in the previous year. “Although revenues in Q1 2020 were slightly lower than the prior year, we expect sales of our specialty diagnostics to begin increasing in Q2, as compared to the same quarterly sales in the previous year," said Zackary Irani, CEO of Biomerica, Inc. “We also expect to be near completion of the enrollment of patients for clinical trials for our H. Pylori diagnostic product in fiscal Q2 and plan to submit to the FDA shortly thereafter. Further, during Q2 we plan to announce important progress in the clinical trials for our diagnostic guided therapy, InFoods® technology, which we expect to make a significant impact on some of the 45 million Americans who suffer from Irritable Bowel Syndrome (IBS).

  • ACCESSWIRE

    The MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • GlobeNewswire

    Biomerica Announces Fiscal Year End 2019 Financial Results

    Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682 versus net sales of $5,564,185 in fiscal 2018. This initial U.S. patent covers the Company’s InFoods® family of products that allow for revolutionary new treatment options for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases.

  • GlobeNewswire

    Republic of Colombia’s food and drug regulatory agency grants clearance for Biomerica’s colorectal cancer screening test to be sold in Colombia

    IRVINE, Calif., Aug. 21, 2019 -- Biomerica, Inc. (Nasdaq: BMRA) announced the Republic of Colombia Ministry of Health and Social Protection Institute National Surveillance of.

  • GlobeNewswire

    Biomerica signs exclusive distribution agreement in China for its colorectal screening test with total minimum purchase requirement of $17 million over 7 years and an upfront pre-payment of $1 million.

    MaxHealth to distribute Biomerica’s colorectal screening test to help identify the early warning signs of colorectal cancer. IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million over the initial seven year term and further requires an upfront pre-payment of $1 million after meeting certain conditions.

  • GlobeNewswire

    Biomerica Announces Third Quarter Financial Results

    Biomerica, Inc. (BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018.  Sales for the three months ending February 28, 2019 were $1,261,161 compared to $1,375,666 for the period ended February 28, 2018.  In addition, the Company announced progress in both its InFoods® IBS clinical study and H. pylori study as well as the issuance of its first patent pertaining to the Company’s InFoods® family of products that are designed to allow for a revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. “We are very pleased that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products.  The patent validates the unique InFoods product which is designed to allow physicians to offer new and better therapies to patients.

  • GlobeNewswire

    Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)

    Biomerica, Inc. (BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products that allow for revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application (#15/526,240) contains numerous claims that broadly cover a product that enables physicians to identify patient specific foods (e.g.

  • ACCESSWIRE

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • GlobeNewswire

    Biomerica Announces Updates for H. Pylori Clinical Studies

    Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the regulatory pathway for final FDA clearance of the Company’s H. pylori product, the Company needs less than 40 clinical trial patient samples in addition to the 210 samples already collected.  These final clinical patient samples are expected to be collected over the next few months, after which the Company will complete the remaining analytical and clinical agreement studies and prepare a submission to the FDA for 510(k) FDA clearance. Helicobacter pylori (H. pylori) infection is one of the most common, chronic, bacterial infections affecting humans.  Complications associated with H. pylori infections include ulcers, inflammation of the stomach lining and stomach cancer.  The diagnosis of H. pylori is important given that specific antibiotic treatment is highly effective in improving outcomes.

  • GlobeNewswire

    Biomerica Announces Second Quarter Financial Results

    Biomerica, Inc. (BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636  for the same period in the previous year.  Net sales were $2,773,661 for the six months ended November 30, 2018 compared to $3,058,119 for the same period in last year.  The Company ended the quarter with approximately $798,000 in backlog for open orders, which were not shipped as of November 30, 2018. Biomerica announced a net loss for the three months ended November 30, 2018 of $477,244, or $0.05 per share, versus a net loss of $268,661, or $0.03 per share, in the previous fiscal year during the same quarter.  The net loss for the six months ended November 30, 2018 was $928,984, or $0.10 per share, compared to net loss of $475,720, or $0.06 per share in the prior fiscal year.

  • GlobeNewswire

    Medline and Biomerica sign agreement for distribution of Biomerica’s colorectal screening test to help identify an early warning sign of colorectal cancer

    Biomerica, Inc. (BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect™ colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies.  Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).